CORC

浏览/检索结果: 共11条,第1-10条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
基于组学研究线纹海马生长发育相关基因的调控机制 学位论文
硕士, 2017
作者:  屈宏越
收藏  |  浏览/下载:44/0  |  提交时间:2018/09/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:34/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:41/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:34/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:30/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:35/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:26/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:16/0  |  提交时间:2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E
收藏  |  浏览/下载:7/0  |  提交时间:2018/07/26
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms 期刊论文
Cancer Treatment Reviews, 2017, 卷号: 54, 页码: 24-33
作者:  Peng, Mei*;  Darko, Kwame Oteng;  Tao, Ting;  Huang, Yanjun;  Su, Qiongli
收藏  |  浏览/下载:13/0  |  提交时间:2019/12/03
AIs  aromatase inhibitors  AMPK  Adenosine Monophosphate-Activated Protein Kinase  AR  androgen  ATM  Ataxia Telangiectasia Mutated  ATP  Adenosine Triphosphate  BCSS  breast cancer specific survival  CK-MB  Creatine Kinase-MB  CREB1  cAMP Response Element-Binding Protein 1  CSC  cancer stem cell  DFS  disease-free survival  DHFU  dihydrofluorouracil  DPD  dihydropyrimidine dehydrogenase  EpCAM  Epithelial Cell Adhesion Molecule  ER  estrogen  ERCC1  excision repair cross-complementary 1  ERK  extracellular signal-regulated kinases  EZH2  enhancer of zeste homolog 2  FdUMP  fluorodeoxyuridine monophosphate  FdUTP  fluorodeoxyuridine triphosphate  FHC  ferritin heavy chain  FUTP  fluorouridine triphosphate  HbA1C  hemoglobin A1c  HER  Human Epidermal Growth Factor Receptor  HIF-1α  hypoxia-inducible factor-1α  HK  hexokinase  IGF1R  insulin growth factor 1 receptor  LDH  lactate dehydrogenase  MDA  Muscular Dystrophy Association  MMP  Matrix Metallopeptidase  MRP1  multidrug resistance-associated protein 1  mTOR  mammalian target of rapamycin  MTX  methotrexate  NCCN  National Comprehensive Cancer Network  OS  overall survival  pCR  Pathologic Complete Response  PDGFR  platelet-derived growth factor receptors  PFS  progression-free survival  PKA  protein kinase A  PR  progesterone receptor  RFS  relapse-free survival  SOD  superoxide dismutase  TAM  tamoxifen  TCA  tricarboxlic acid  TS  thymidylate synthase  Combination  Mechanisms  Metformin  Chemotherapeutic drugs  


©版权所有 ©2017 CSpace - Powered by CSpace